Market Capitalization

After a 1-for-12 reverse stock split saved it from delisting, Cre8 Enterprise must now prove its strategic pivot is more than a temporary fix.

The green builder secured its Nasdaq status, but a sharp stock drop reveals market skepticism. Can its $78.5M pipeline convince cautious investors?

The VCT posts flat returns but rewards investors with a special dividend, announcing a new chair as it navigates a shifting regulatory landscape.

Laufenn's new all-terrain tire aims to conquer the competitive mid-range market by blending rugged capability with on-road comfort and an attractive price point.

Once a failing firm, Aurelion Inc. bet its future on tokenized gold. The gamble paid off with a profitable quarter, but regulatory risks loom large.

Daxor reports a transformative year with 45% revenue growth, a new FDA-cleared portable analyzer, and a full pivot to a high-growth medtech company.

MAIA Biotechnology secured a crucial $30M to advance its promising lung cancer drug, but the move sent its stock plunging amid investor fears of dilution.

Klaviyo announces its first-ever $500M buyback, signaling strong financial health and a dual strategy of rewarding investors while fueling AI innovation.

Ag Growth International brings back its 23-year former CFO to the board, signaling a major push for operational excellence amid financial pressures.

Amid intense market volatility, firms are turning to AI-powered energy storage to protect profits. One company's $53M deal shows how it's done.

Fresh off a major clinical trial victory, Alumis Inc. heads to a key investor conference. What's next for its promising pipeline and soaring stock?

After a dramatic pivot and massive fundraising, Galecto will detail its new hematology pipeline at a key conference. Here’s what investors are watching.

With a $6B M&A war chest and a new AI focus, Roper Technologies takes the stage at Morgan Stanley. Here’s what investors will be watching for.

UroGen's new bladder cancer drug sees rapid uptake post-reimbursement code, but a $153M loss and fresh debt highlight its high-stakes growth strategy.

Fidelis Insurance Group completes a $163M repurchase of all shares from founding investor CVC, a move set to boost shareholder value ahead of its rebrand.

With major trials underway for its cancer and vision drugs, NovaBridge's upcoming investor presentation could be a pivotal moment for the biotech firm.

Manhattan's top landlord promotes Harrison Sitomer from intern to President, signaling a focus on stability as it navigates a complex office market.

Hain Celestial completes sale of Terra and Garden of Eatin' to pay down debt, betting its future on the high-margin tea, yogurt, and baby food markets.

The New York-based bank will now originate FHA-insured loans nationwide, positioning it to capitalize on the growing demand for senior care facilities.

As MSA Awareness Month begins, a novel drug from Alterity Therapeutics shows significant promise in slowing the devastating and untreatable neurodegenerative disease.